Insight Molecular Diagnostics Inc. Common Stock vs. Intellia Therapeutics, Inc
IMDX
Insight Molecular Diagnostics Inc. Common Stock
$4.30 -1.83%
VS NTLAIntellia Therapeutics, Inc
$12.44 -6.33%
Insight Molecular Diagnostics Inc. Common Stock and Intellia Therapeutics, Inc are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| IMDX | NTLA | |
|---|---|---|
| Market Cap | $143.33 million | $1.86 billion |
| Revenue (TTM) | — | $59.51 million |
| Net Income (TTM) | — | $-399,975,000 |
NTLA leads on 1 of 1 size & scale factors.
Valuation
| IMDX | NTLA | |
|---|---|---|
| Price / Book | — | 2.56 |
| Price / Sales | — | 31.27 |
IMDX and NTLA split the valuation factors evenly.
Profitability
| IMDX | NTLA | |
|---|---|---|
| Net Margin | — | -672.16% |
| Return on Equity | — | -54.96% |
IMDX and NTLA split the profitability factors evenly.
Risk & Sentiment
| IMDX | NTLA | |
|---|---|---|
| Short Interest | 0.93% | 2.43% |
IMDX leads on 1 of 1 risk & sentiment factors.
Dig deeper: IMDX overview, IMDX financials, NTLA overview, NTLA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.